Wockhardt Q4 profit down 78 per cent on import bans

Drugmaker Wockhardt Ltd on Monday reported a 78 per cent slump in March-quarter profit, as it continues to reel under the US and UK import bans due to manufacturing quality lapses.

The company's January-March net profit fell to 744.5 million rupees ($12.76 million) compared with 3.35 billion rupees a year earlier. Analysts on average had expected fourth-quarter profit of 747 million rupees, according to Thomson Reuters data.

Sales fell 30 percent to 10.4 billion rupees in the quarter.

In November, the U.S. Food and Drug Administration (FDA) issued an import alert, effectively a ban, against Wockhardt's Chikalthana plant in western India. The FDA had imposed a ban on the company's Waluj plant in May.

The United States is Wockhardt's largest market.


  • Monetary policy review needs to look beyond key policy rate

    After changes in the interest rate cycle direction, expectation of some action on rates is high before every monetary policy review of the Reserve Ban


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Arun Kumar Jain

India in a new age work order

There are three broad categories of people in the world ...

Rajgopal Nidamboor

The balancing act of nature

It’s a fact of modern life that you and I ...

Dharmendra Khandal

For a lark, let's do something serious finally

It’s a sight to behold. As you drive through a ...


William D. Green

Chairman & CEO, Accenture